Yale University/Yale Cancer Center

New Haven, Connecticut 06520-8327

11 studies enrolling now · 36 studies all time

What they study most

Acute Myelogenous Leukemia, Advanced Breast Cancer, Advanced Renal Cell Carcinoma, Advanced Solid Tumor, Advanced Solid Tumors, Advanced or Metastatic Solid Tumors, Anaplastic Astrocytoma, B Cell Lymphoma, BRAF V600E-mutant Metastatic Colorectal Cancer, BRCA Mutation, BRCA1 Mutation, BRCA2 Mutation

Studies at this site

• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) — Recruiting now
• A Study of BG-C477 in Participants With Advanced Solid Tumors — Recruiting now
• A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. — Recruiting now
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer — Recruiting now
• A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) — Recruiting now
• Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors — Recruiting now
• A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors — Recruiting now
• A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer — Recruiting now
• ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies — Recruiting now
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies — Recruiting now
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors — Recruiting now
• Study of SGR-3515 In Participants With Advanced Solid Tumors. — Recruiting now
• GEN1047 for Solid Tumors - First in Human (FIH) Trial — Stopped early
• Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy — Running, not enrolling
• A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer — Running, not enrolling
• Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer — Completed
• Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial — Paused
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments — Completed
• The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC — Completed
• CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC — Running, not enrolling
• Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy — Running, not enrolling
• Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma — Completed
• KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors — Stopped early
• Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors — Stopped early
• Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) — Running, not enrolling
• Study of ALE.C04 in Patients With Head and Neck Cancer — Stopped early
• Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation — Running, not enrolling
• Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy — Completed
• Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies — Stopped early
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
• Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer — Completed
• Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma — Completed
• Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer — Stopped early
• The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma — Stopped early
• Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies — Stopped early
• Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer — Completed